Cefpodoxime

Cefpodoxime

Cefpodoxime
Systematic (IUPAC) name
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Generic (formerly Vantin)
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 50%
Protein binding 21% to 29%
Metabolism Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Biological half-life 2 hours
Excretion Renal, unchanged
Identifiers
CAS Registry Number  Y
ATC code J01
PubChem CID:
DrugBank  N
ChemSpider  Y
UNII  N
KEGG  Y
ChEBI  N
ChEMBL  Y
Chemical data
Formula C15H17N5O6S2
Molecular mass 427.458 g/mol
 N   

Cefpodoxime is an oral, third-generation Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the USA, according the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.

Pfizer, the parent company of Pharmacia & Upjohn, markets cefpodoxime proxetil under the trade name C-Doxim for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.

Finecure, India markets the products under trade name Cefpo.[1]

Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

Structural formula of cefpodoxime proxetil

Contents

  • Spectrum of bacterial susceptibility and resistance 1
  • Brand Name 2
  • References 3
  • External links 4

Spectrum of bacterial susceptibility and resistance

Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: ≤0.03 - 1 μg/ml
  • Neisseria gonorrhoeae: 0.004 - 0.06 μg/ml
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml

[2]


Brand Name

Brand Name: Toraxim (Delta Pharma Ltd. Bangladesh)

References

  1. ^ "Anti Biotics and Anti Bacterial". Finecurepharmaceuticalsltd. Retrieved 2012-03-27. 
  2. ^ http://www.toku-e.com/Assets/MIC/Cefpodoxime%20Free%20acid.pdf

External links

  • PubChem 6526396 - cefpodoxime proxetil
  • Vantin Tablets and Oral Suspension Torpod (Torrent)Full U.S. Prescribing Information (from manufacturer's website)
  • Simplicef (from manufacturer's website)
  • http://www.intaspharma.com/index.php?option=com_djcatalog2&view=itemstable&cid=3&Itemid=77